BLPharma Product 3

EPIVYN is a novel patented anti-cancer drug developed by Black Lion Pharmaceuticals. Our breakthrough molecule is a novel class of cancer drug with enhanced cancer killing properties at very low dosage levels. The advantage of our proprietary biotechnology renders a product with highly efficient cancer-cell killing capabilities at dosage levels that elicit low toxicity to other non-cancer cells.

Our comparative research clearly demonstrates that very low dosage levels of EPIVYN are equivalent in cancer killing effects to higher doses (100 times higher) of Cisplatin and Methotrexate, both of these compounds are first barrier treatment drugs that are used to treat patients in hospitals across America and the world. Cisplatin global sales exceed one billion dollars annually.

How toxic are the current chemotherapies used in hospitals today?

They are very toxic. The dangerous toxic side effects of most chemotherapy drugs are many times harder on patients than most of the symptoms caused by the disease itself. Including loss of vision, hair, hearing, voting, dementia and other profound undesirable side effects. Most chemotherapy agents are cellular poisons that kill malignant cells, however they can’t differentiate between good and bad cells and they end up killing millions of healthy cells too causing severe and many times irreversible damage to the patient’s health.

Despite the fact that all American cancer patients undergo oncology treatment the American Cancer Society estimates that in 2007 more than 559,000 patients will die in the United States only due to cancer (an average of 1,530 deaths daily).